Join our daily newsletter At The Bell to receive exclusive market insights
- Uscom (UCM) has received key European CE mark approval for its Uscom digital ultrasonic SpiroSonic AIR spirometer
- The technology uses Uscom’s patented multi-path digital ultrasonic technology to assess asthma, occupational lung disease and post-COVID syndrome
- Uscom intends to roll the product out for sale to its growing distribution networks in Europe and south-east Asian markets
- The approval comes at the end of an 18-month process, which the company says was complicated by the COVID-19 pandemic and repeated changes in CE regulations
- Company shares last traded at 13.5 cents
Uscom (UCM) has received European CE mark approval for its Uscom digital ultrasonic SpiroSonic AIR spirometer.
The CE mark is recognition of legal compliance with health, safety and environmental standards and is essential for sale of new medical technologies into the European market and many southeast Asian jurisdictions.
The approval comes at the end of an 18-month process, which the company says was complicated by the COVID-19 pandemic and repeated changes in CE regulations.
The technology uses Uscom’s patented multi-path digital ultrasonic technology to assess asthma, occupational lung disease and post-COVID syndrome.
“The spirometry market is predicted to increase around 160% over the next 6 years to $6.5B, making this a very exciting time for Uscom to bring the world leading SpiroSonic AIR to market,” said Uscom Executive Chairman, Professor Rob Phillips.
“The SpiroSonic AIR is accurate, easy to use, and provides research quality non-invasive lung function testing for patients with asthma, COPD, occupational lung disease and post COVID syndrome, and can be used in the lab, clinic or home.”
Uscom intends to roll the product out for sale to its growing distribution networks in Europe and south-east Asian markets.
UCM shares were trading flat at 13.5 cents today.
